MAZE
Maze TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MAZE
Maze Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing genetics-based precision therapeutics
171 Oyster Point Blvd., Suite 300, South San Francisco, California 94080
--
Maze Therapeutics, Inc. was incorporated under the laws of the State of Delaware on August 29, 2017. The company is a clinical-stage biopharmaceutical company that leverages the power of human genetics to develop novel small molecule precision medicines for patients with renal, cardiovascular and related metabolic or CVRM diseases, including obesity. The company is advancing a pipeline using their Compass platform, which allows them to identify and characterize genetic variants in diseases, and then link these variants to biological pathways that drive disease in specific patient populations through a process the company calls mutation functionalization. Their compass platform is built to inform all stages of the drug discovery and development process through clinical trial design. The company is currently advancing two wholly-owned lead projects, MZE 829 and MZE 782, each representing a new precision medicine-based approach to chronic kidney disease (CKD).
Company Financials
EPS
MAZE has released its 2025 Q3 earnings. EPS was reported at -0.66, versus the expected -0.69, beating expectations. The chart below visualizes how MAZE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
